ArticleProceedings of the National Academy of Sciences of the United States of America2004
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 148 citations in OpenAlex.
- Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.Cancer immunology, immunotherapy : CII · 2011Trial
- Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.Cancer immunology, immunotherapy : CII · 2006Trial
- A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients.Cancer immunology, immunotherapy : CII · 2006Trial
- Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.Human cell · 2020Article
- Therapeutic cancer vaccine: building the future from lessons of the past.Seminars in immunopathology · 2019Review
- AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma.Oncotarget · 2016Article
- TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Oncoimmunology · 2016Article
- The melanoma-associated antigen 1 (MAGEA1) protein stimulates the E3 ubiquitin-ligase activity of TRIM31 within a TRIM31-MAGEA1-NSE4 complex.Cell cycle (Georgetown, Tex.) · 2015Article
- MAGE proteins regulate KRAB zinc finger transcription factors and KAP1 E3 ligase activity.Archives of biochemistry and biophysics · 2014Article
- Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.Nature reviews. Cancer · 2014Review
- Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.Frontiers in oncology · 2014Article
- Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.International journal of clinical and experimental pathology · 2014Article
- MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells.International journal of clinical and experimental pathology · 2014Article
- Cancer vaccines: Looking to the future.Oncoimmunology · 2013Article
- Advances in T-cell epitope engineering.Frontiers in immunology · 2013Article
- Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Nature reviews. Urology · 2012Review
- Defining the critical hurdles in cancer immunotherapy.Journal of translational medicine · 2011Article
- Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.Cancers · 2011Article
- Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.Cellular and molecular life sciences : CMLS · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cancer-germline gene MAGE-3 codes for tumor-specific antigens recognized on many tumors by T lymphocytes. A MAGE-3 antigen presented by HLA-A1 has been used in several vaccination trials on metastatic melanoma patients. Only a small minority of patients have shown evidence of tumor regression. Attempts to correlate the tumor rejections with the cytotoxic T lymphocyte (CTL) response against the vaccine have been hampered by the low level of these responses. In noncancerous individuals, the frequency of the T cell precursors against antigen MAGE-3.A1 is approximately 4 x 10(-7) CD8 T cells. The diversity of the T cell receptor repertoire of these anti-MAGE-3.A1 precursors was analyzed in one individual. The results indicate that it is very likely that the repertoire comprises >100 clonotypes. On this basis, it is possible to use not only the frequency of CTL precursors in the blood but also the presence of dominant clonotypes to ascertain in patients the existence of anti-MAGE-3.A1 responses as low as 10(-6) of CD8. With this approach, we observed a correlation between tumor regression and anti-MAGE-3.A1 CTL responses in patients vaccinated with a recombinant virus encoding the antigen and also in patients vaccinated with peptide-pulsed dendritic cells. In contrast, for patients showing tumor regression after vaccination with peptide alone, CTL responses were almost never observed. It is possible that even those CTL responses that are below our present detection level can trigger a sequence of events that leads to tumor regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.